SHARP
6.1.2020 00:05:13 CET | Business Wire | Press release
Sharp Corporation (TOKYO:6753) is set to return to CES 2020 with an exhibit showcasing the latest installments in its evolving ecosystem of products and services that leverage the benefits of Ultra-HD 8K video and advanced 5G wireless technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200105005022/en/
Sharp’s 8K+5G Ecosystem comprises end-to-end solutions for the recording, editing, storage, and delivery of 8K content, with potential benefits extending far beyond entertainment and broadcasting to such diverse fields as industry, security, health, education, automotive, smart offices, and smart homes. One much-anticipated addition to a constantly expanding portfolio of 8K products and services is the new dynabook 8K video editing PC system, which with its 15.6-inch screen will provide a compact, convenient, prosumer-ready platform for the viewing and processing of 8K materials.
Meanwhile, striking examples of Sharp’s 8K+5G Ecosystem on display at CES 2020 will include a drone-mounted system developed in conjunction with various external stakeholders for the real-time capture and transmission of 8K footage for purposes including racehorse training and infrastructure surveys. It’s one of various cross-disciplinary collaborations currently undergoing trials in order to bring the practical benefits of 8K and 5G directly to businesses and consumers.
“Collaborations are a pillar of our efforts to leverage the benefits of 8K+5G,” says Bob Ishida, Executive Vice President and Head of ICT Group. “We are conducting trials with a range of external partners, all with the aim of realizing a comprehensive 8K+5G ecosystem as soon as possible. And as our CES 2020 exhibit will show, we firmly believe that, in conjunction with the introduction of 5G, our 8K technology can make a major contribution to the society of the future.”
Learn more about Sharp at CES 2020: https://global.sharp/brand/globalevents/ces2020/
About Sharp
Sharp Corporation is a worldwide developer of innovative products and core technologies that play a key role in shaping the future of electronics. Sharp sets its business vision as “Changing the World with 8K+5G and AIoT.” 8K technology creates images that reveal a world beyond our everyday reality and gives birth to thrilling new discoveries. AIoT connects people and society through artificial intelligence and IoT technology. Being the origin of countless innovations, through these ideas, Sharp will continue to revolutionize the world. Sharp Corporation employs 52,640 people around the world (as of September 30, 2019) and recorded consolidated annual sales of 2.4 trillion yen for the fiscal year ended March 31, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200105005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom